Abstract

The present invention relates to an ophthalmic composition, comprising a nonionic oil-in-water emulsion with: • an aqueous phase Aq, • a lipid phase L, in the form of droplets dispersed in the aqueous phase, • an interface between said lipid phase L and said aqueous phase Aq, and • a particulate surface-active agent for stabilizing the emulsion, located at the interface between the lipid phase and the aqueous phase, said surface-active agent comprising or consisting of organic particles with an average size of less than or equal to 1 μm, said composition being free of non-particulate surfactant, and advantageously free of preservative. These compositions are useful as a medicament, in particular for administration by ocular instillation. The invention also relates to a method for preparing said compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions

Abstract

{X ii } i=1, ni=1, n l tottot l tottot (X ii , E, D, A) — il λλmm(l unifunif (Z ii mm)l registregist (Z ii mm, A ii ))λλss(l unifunif (Z ii ss)l alignalign (z ii ss, A ii ))X ii EDZ ii Z ii E(X ii )zzmmzzsssim(X ii , X ll )λλmmλλss l(zl(zjj mm )Sk(ζ1, ζ2)Sk(ζ1, ζ2)12l alignalign Sk(ζ 11 A0A0, ζ 22 A0A0)Sk(ζ 11 A1A1, ζ 22 A1A1), ), where ζ40and ζ41} are the observations obtained from ζ and in the groups A = 0, namely the second group or negative group, and A = 1, namely the first group or positive group, where the ζ4011 A022 A0} of similar size and where the ζA111 A122 A1 l registregist = Sk {ζA0, ζA1}.

Abstract

The invention relates to a method for detecting electric arcs in an electrical circuit of an aeronautical system, which method comprises a first phase (P1) of identifying recurring patterns in the behaviour of the electric current, on an electric line of the electrical circuit, and storing the recurring patterns in a pattern database, and a second diagnostic phase (P2) which involves comparing the behaviour of the electric current on the electric line with recurring patterns stored in the pattern database, and detecting an electric arc when the behaviour does not correspond to a recurring pattern stored in the pattern database.

IPC Classes  ?

• G01R 31/00 - Arrangements for testing electric propertiesArrangements for locating electric faultsArrangements for electrical testing characterised by what is being tested not provided for elsewhere
• G01R 31/12 - Testing dielectric strength or breakdown voltage

Abstract

3mixRmixRmixR33-Ar, for upcycling a plastic or a mixture of plastics.

IPC Classes  ?

• C08K 5/28 - Azides
• C08K 5/3492 - Triazines
• C08L 23/04 - Homopolymers or copolymers of ethene

Abstract

The invention relates to a method for determining at least one component of the positioning of a receiver (24) relative to a transmitter (22), the transmitter (22) comprising at least two magnetic generators (30, 32, 34), the method comprising the following steps: - measuring a resulting magnetic field; - demodulating the measurement signal so as to determine a plurality of candidate measurements; - applying, to each candidate measurement, a correction that aims to compensate for a directional orthogonality defect in the magnetic generators (30, 32, 34) so as to obtain a corresponding corrected measurement; - calculating a value representative of the likelihood that this candidate measurement reflects the actual contributions of each alternating magnetic field; - selecting a selected measurement corresponding to the highest likelihood; and - determining the at least one component of the positioning of the receiver (24).

IPC Classes  ?

• G01S 1/04 - Beacons or beacon systems transmitting signals having a characteristic or characteristics capable of being detected by non-directional receivers and defining directions, positions, or position lines fixed relatively to the beacon transmittersReceivers co-operating therewith using radio waves Details
• G01R 33/00 - Arrangements or instruments for measuring magnetic variables
• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
• G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinationsPosition-fixing by co-ordinating two or more distance determinations using radio waves

Abstract

The invention relates to a method for characterising microorganisms which comprises: A. for each wavelength of a predetermined set of wavelengths comprising at least one wavelength, acquiring a holographic digital image, generating a focused image by computer means, each pixel of which image comprises an amplitude value and a phase value, and segmenting the focused image so as to extract portions corresponding to microorganisms; and B. characterising the microorganisms by computer means, according to the focused image portions. According to the invention, prior to the characterisation or prior to the segmentation or prior to the generation of the focused image, the method comprises correcting optical aberrations of the acquisition device by computer means, and the characterisation of the microorganisms comprises applying a digital model to these portions having as descriptors the amplitude and/or phase values of each wavelength of the predetermined set of wavelengths.

IPC Classes  ?

• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G03H 1/26 - Processes or apparatus specially adapted to produce multiple holograms or to obtain images from them, e.g. multicolour technique
• G01N 15/1433 - Signal processing using image recognition
• G01N 15/1434 - Optical arrangements
• G01N 15/10 - Investigating individual particles
• G03H 1/08 - Synthesising holograms
• G06T 7/00 - Image analysis
• G06V 10/143 - Sensing or illuminating at different wavelengths
• G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a patternLocating or processing of specific regions to guide the detection or recognition
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

A medical device for penetrating an anatomic structure, e.g., a bone structure, including a processing unit programmed to execute one or more statistical algorithms, e.g., Bayesian-based perforation detection algorithms, with electrical conductivity measured during penetration of an anatomic structure as an input to detect a breach condition, e.g., a spinal canal perforation, based on the measured electrical conductivity. The medical device may include a drill bit having sensing capabilities coupled to the distal end of a robot arm via a power drill unit mounted on the robot arm. The power drill unit may cease transmission of rotary motion to the drill bit upon detection of the breach condition.

IPC Classes  ?

• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans
• A61B 34/30 - Surgical robots
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to new caged pyranine fluorophores of the following formula (I), (I) or a salt thereof, and to composition comprising thereof. or a salt thereof. Another object of the invention relates to a method for measuring a light intensity of a light source in a medium using caged pyranine fluorophores or composition comprising thereof. The present invention also concerns a new method for preparing caged pyranine fluorophores.

IPC Classes  ?

• C07D 295/26 - Sulfur atoms
• C07C 57/00 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The invention relates to a microwave sensor (2) for detecting at least one target gas, the sensor comprising: a substrate (4); a microwave device (5) printed on the substrate (4) and having a deposition opening (7); and a liquid substance (8) sensitive to the at least one target gas, the liquid substance (8) being arranged in the deposition opening (7) so as to be in contact with the microwave device (5), the liquid substance (8) being a deep eutectic solvent and chosen such that the presence of the at least one target gas causes at least one of a change in the dielectric characteristics or a change in the electrical characteristics of the liquid substance (8), resulting in a change in the distribution parameters of the microwave device (5).

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 22/00 - Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises activating the Xc- transporter or the GPX4 enzyme in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61P 27/02 - Ophthalmic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises activating the Xc- transporter or the GPX4 enzyme in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61P 27/02 - Ophthalmic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention provides a method for preparing a model of cone degeneration, comprising a step of activating a specific cell death in at least one cone photoreceptor. Also provided are methods for isolating compounds capable of protecting conae photoreceptors from degeneration.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 27/02 - Ophthalmic agents
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction or inhibition of lipid peroxidation in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction of intracellular iron levels in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides a method for preparing a model of cone degeneration, comprising a step of activating a specific cell death in at least one cone photoreceptor. Also provided are methods for isolating compounds capable of protecting conae photoreceptors from degeneration.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 27/02 - Ophthalmic agents
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction of intracellular iron levels in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction or inhibition of lipid peroxidation in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The invention relates to a power amplifier comprising a power divider (2), a plurality of amplifying channels (3) and a power combiner (1), the power combiner comprising a first subcombiner (4), a second subcombiner (5), a plurality of input couplers (6) and an output coupler (7), the first subcombiner (4) comprising a first cylindrical cavity (8) along an axis of symmetry (Z) and a first plurality of waveguides (9) extending radially from the first cylindrical cavity (8), the second subcombiner (5) comprising a second cylindrical cavity (10) along the same axis of symmetry (Z) and a second plurality of waveguides (11) extending radially from the second cylindrical cavity (10), each input coupler (6) being configured to receive an amplified elementary signal from an amplifying channel (3) and to divide it into a first signal transmitted through a waveguide (9) and a second signal transmitted through a waveguide (11).

IPC Classes  ?

• H01P 5/12 - Coupling devices having more than two ports
• H03F 3/60 - Amplifiers in which coupling networks have distributed constants, e.g. with waveguide resonators
• H01P 1/18 - Phase-shifters
• H01P 5/22 - Hybrid ring junctions

Abstract

The present invention relates to a method for treating a material comprising one or more silicone elastomers, the method comprising a step of decrosslinking the material in the presence of a metal catalyst and of a solvent selected from the group consisting of alcohols, carboxylic acids, esters, ethers, and mixtures thereof, resulting in the formation of a mixture comprising fragmented chains of silicone elastomer.

IPC Classes  ?

• C08J 11/22 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds
• B01J 31/22 - Organic complexes
• C07F 7/08 - Compounds having one or more C—Si linkages
• C08G 77/10 - Equilibration processes
• C08G 77/38 - Polysiloxanes modified by chemical after-treatment
• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters

Abstract

The present invention relates to a cosmetic method for delivering ascorbic acid and/or one of its derivatives through the skin via iontophoresis, preferably bipolar iontophoresis, and/or electrostimulation, the method comprising the following steps: • providing a device comprising a main electrode, a counter-electrode and a power source electrically connected to the main electrode on the one hand and to the counter-electrode on the other hand, the main electrode and the counter-electrode being intended to be in direct or indirect contact with the skin and being separated from one another by a free space; • applying a cosmetic composition comprising ascorbic acid and/or one of its derivatives and one or more cosmetically acceptable additives to the main electrode and the counter-electrode but not to the free space; • applying the device to the skin such that the main electrode and the counter-electrode with the cosmetic formulation are in direct or indirect contact with the skin; • applying, over a certain time period, a direct current with an average current density of 0.03 mA/cm2 to 0.5 mA/cm2, preferably 0.1 mA/cm2 to 0.2 mA/cm2. The present invention also relates to an iontophoresis kit for implementing this method.

IPC Classes  ?

• A61N 1/30 - Apparatus for iontophoresis or cataphoresis
• A61N 1/04 - Electrodes
• A61K 8/67 - Vitamins
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61Q 19/00 - Preparations for care of the skin
• A45D 44/00 - Other cosmetic or toiletry articles, e.g. for hairdressers' rooms

Abstract

The invention relates to a balloon cuff (1) for a tracheal intubation device, the balloon cuff (1) being elastically deformable and extending between an inner surface (3) surrounding an axis (A) and an outer surface (5) surrounding the inner surface (3), the balloon cuff (1) comprising inner walls that define ducts (13, 15) that extend through the balloon cuff, the balloon cuff (1) being configured to go from a deflated state to an inflated state by injecting a fluid into the ducts (13, 15) such that the outer surface (5) moves away from the axis.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

The present invention concerns a novel fusion polypeptide comprising a polypeptide having an N- glycosidase activity fused to an antioxidant moiety, wherein the polypeptide having an N-glycosidase activity is a polypeptide from a bacterium belonging to the Acidobacteria phylum, preferably to the Acidobacteriia class. The present invention also concerns the nucleic acid molecule, vector, and host cell encoding the fusion polypeptide, as well as compositions and kits thereof. The present invention also provides methods for purifying and/or for producing the fusion polypeptide, as well as in vitro use of the fusion polypeptide, or the nucleic acid molecule, vector, or host cell encoding the fusion polypeptide, or compositions thereof.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

Provided herein is a novel bacterial strain isolated from groundwater, as well as bacterial extracts thereof which are useful for preventing and/or treating cutaneous inflammatory diseases, notably dermatological pathologies. Also provided are cosmetic or dermatological compositions containing such a bacterial extract as an active agent.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria

Abstract

The present invention relates to particles comprising at least one monosaccharide modified with a hydrophobic chain, at least one cyclodextrin and optionally a molecule of therapeutic or cosmetic interest, to the preparation method thereof, to a pharmaceutical or cosmetic composition comprising same, and to the use thereof for the sustained release of molecules of cosmetic or therapeutic interest. The invention also relates to the aforementioned modified monosaccharide.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• C08L 5/16 - CyclodextrinDerivatives thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/107 - Emulsions

Abstract

The present disclosure relates to conjugates of catechol-based siderophores with cargo molecules, such as antibiotics or fluorophores, and to the preparation and uses thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 49/00 - Preparations for testing in vivo
• A61P 31/04 - Antibacterial agents
• C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
• C07D 223/12 - Nitrogen atoms not forming part of a nitro radical
• C07D 277/10 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• C07D 491/16 - Peri-condensed systems
• C07D 493/10 - Spiro-condensed systems
• C07D 498/08 - Bridged systems
• C07D 499/64 - Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms

Abstract

22 groups; performing in situ synthesis of a polyimide by reactive extrusion of the components wherein the residence time is less than 10 minutes; and recovering a polyamide-polyimide blend being a reinforced polyamide comprising a continuous polyamide phase and a polyimide dispersed phase.

IPC Classes  ?

• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08J 3/00 - Processes of treating or compounding macromolecular substances
• C08L 77/00 - Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chainCompositions of derivatives of such polymers
• C08L 77/02 - Polyamides derived from omega-amino carboxylic acids or from lactams thereof
• C08L 79/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08G 73/14 - Polyamide-imides
• C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material

Abstract

The disclosure relates to a ductile polyamide and to a process to produce a ductile polyamide comprising providing components comprising one or more polyamides, one or more dianhydrides, and one or more diamines; wherein the one or more polyamides are provided at a content of at least 60 wt.% based on the total weight of the components; and wherein the one or more polyamides comprise at least one polyamide having amide groups separated by less than 10 carbon atoms; performing in situ synthesis of a polyimide by reactive extrusion of the components wherein the residence time is less than 10 minutes; and recovering a polyamide-polyimide blend being a ductile polyamide comprising a continuous polyamide phase and a dispersed polyimide phase.

IPC Classes  ?

• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08J 3/00 - Processes of treating or compounding macromolecular substances
• C08L 77/00 - Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chainCompositions of derivatives of such polymers
• C08L 77/02 - Polyamides derived from omega-amino carboxylic acids or from lactams thereof
• C08L 79/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors

Abstract

Provided herein are oligourea foldamers comprising the sequence of Ac-LUEULUKUPULUEULUKUAU2 2 (SEQ ID NO: 1) or Ac-LUEULUKUAULUEULUKUAU22 (SEQ ID NO: 2), and permeable membranes comprising thereof. Also provided herein is a method of purifying water using the permeable membranes.

IPC Classes  ?

• C08L 75/02 - Polyureas
• B01D 71/54 - PolyureasPolyurethanes
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

The invention relates to a Mach-Zehnder interferometric device (1), comprising: - at least a first prism (2) and a second prism (3), - the prisms (2, 3) being joined together so as to form one piece, the prisms (2, 3) forming a beam-splitting interface (4) therebetween, the splitting interface (4) being parallel to a first external face (5) of the first prism (2) and a second external face (6) of the second prism (3), - at least one of the prisms (2, 3) comprising an entrance face (11) for receiving an incident light beam, the splitting interface (4) being configured to divide the incident beam into two partial beams, the first and second external faces (5, 6) each being configured to reflect all or some of one of the partial beams, and - the prisms (2, 3) each comprising an exit face (15, 16) allowing a first and a second exiting light beam (20, 21) to exit, respectively; and - a spatial filter (9) configured to form a reference beam from one of the partial beams, the device (1) being configured to make the reference beam and the other of the partial beams interfere to form the exiting beams (20, 21).

IPC Classes  ?

• G01B 9/02 - Interferometers
• G01B 9/02097 - Self-interferometers
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces
• G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for
• G02B 5/04 - Prisms
• G02B 27/14 - Beam splitting or combining systems operating by reflection only
• G01J 3/45 - Interferometric spectrometry
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details

Abstract

22 ranging from 10.0 to 600.0 g/10 min as determined according to ISO 1133-2011 at 230 °C under a load of 2.16 kg; an Mz below 1,000,000 g/mol as determined by size exclusion chromatography; an Mw/Mn ranging from 2.2 to 10.0 as determined by size exclusion chromatography a ratio of complex viscosity at a frequency of 0.01 rad/sec to the complex viscosity at a frequency of 100 rad/sec of at most 8.0, said ratio being measured at 190°C; and a tan delta at 0.1 rad at 190°C above 2.5.

IPC Classes  ?

• B29C 45/00 - Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mouldApparatus therefor
• B29C 48/275 - Recovery or reuse of energy or materials
• B29C 48/40 - Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws, e.g. twin screw extruders
• B29C 48/57 - Screws provided with kneading disc-like elements, e.g. with oval-shaped elements
• B29C 48/625 - Screws characterised by the ratio of the threaded length of the screw to its outside diameter [L/D ratio]
• B29C 48/80 - Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
• B29C 48/875 - Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling for achieving a non-uniform temperature distribution, e.g. using barrels having both cooling and heating zones
• B29C 48/92 - Measuring, controlling or regulating
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics

Abstract

A process to produce a polymer composition comprising providing from 10 to 90 wt.% of a component A being one or more polypropylene resins; from 90 to 10 wt.% of a component B being one or more materials having a polar functional group, polymers having a polar functional group, natural fibres, and any mixture thereof; and from 0.5 to 20 wt.% of a compatibilizer, and melt blending the components and the compatibilizer to obtain a polymer composition; wherein the compatibilizer is a grafted blend of polyethylene and polypropylene comprising from 5 to 90 wt.% of polyethylene, has a melt index MI2 ranging from 5.0 to 200.0 g/10 min according to ISO 1133-2011 at 190 °C under a load of 2.16 kg a complex viscosity at 0.1 rad/sec at 190 °C of at most 1,000 Pa·s; and a grafting agent content ranging from 0.3 to 5.0 wt.%.

IPC Classes  ?

• C08L 23/14 - Copolymers of propene
• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08F 299/02 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates
• C08J 3/00 - Processes of treating or compounding macromolecular substances
• C08J 3/20 - Compounding polymers with additives, e.g. colouring
• C08F 8/46 - Reaction with unsaturated dicarboxylic acids or anhydrides thereof, e.g. maleinisation
• C08L 23/28 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers modified by chemical after-treatment by reaction with halogens or halogen-containing compounds

Abstract

The disclosure provides a process for the treatment of an initial polypropylene-containing material to produce a polypropylene composition comprising the steps of providing a twin screw extruder with thermal regulation devices; providing an initial polypropylene-containing material comprising at least 50 wt.% of polypropylene; extruding the initial polypropylene- containing material to obtain a polypropylene composition; and recovering a polypropylene composition; wherein the step of extruding comprises a thermal treatment of the initial polypropylene-containing material at a maximum barrel temperature Ts of at least 345°C in one or more hot zones of the extruder by self-heating.

IPC Classes  ?

• B29C 45/00 - Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mouldApparatus therefor
• B29C 48/275 - Recovery or reuse of energy or materials
• B29C 48/40 - Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws, e.g. twin screw extruders
• B29C 48/57 - Screws provided with kneading disc-like elements, e.g. with oval-shaped elements
• B29C 48/625 - Screws characterised by the ratio of the threaded length of the screw to its outside diameter [L/D ratio]
• B29C 48/80 - Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
• B29C 48/875 - Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling for achieving a non-uniform temperature distribution, e.g. using barrels having both cooling and heating zones
• B29C 48/92 - Measuring, controlling or regulating
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• B29B 7/00 - MixingKneading
• B29B 7/48 - MixingKneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
• B29B 7/82 - Heating or cooling

Abstract

The disclosure relate to a process for grafting a polypropylene-containing material to produce a modified polypropylene composition comprising the steps of providing an extruder with thermal regulation devices; providing a polypropylene-containing material comprising at least 50 wt.% of polypropylene based on the total weight of the polypropylene-containing material; providing a grafting agent in a content ranging from 0.8 to 10.0 wt.% based on the total weight of the polypropylene-containing material provided in step (b), wherein the grafting agent comprises at least one double bound per molecule; extruding the polypropylene-containing material and the grafting agent to obtain a modified polypropylene composition; wherein said step comprises a thermal treatment of the polypropylene-containing material at a maximum barrel temperature Ts of at least 345 °C to at most 440°C in one or more hot zones of the extruder; and recovering a modified polypropylene composition.

IPC Classes  ?

• C08F 8/46 - Reaction with unsaturated dicarboxylic acids or anhydrides thereof, e.g. maleinisation
• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08J 3/20 - Compounding polymers with additives, e.g. colouring

Abstract

The disclosure provides a modified polypropylene composition comprising at least 50 wt.% of polypropylene based on the total weight of the modified polypropylene composition, remarkable in that the modified polypropylene composition has a melt index MI2 ranging from 10.0 to 600.0 g/10 min as determined according to ISO 1133- 2011 at 230 °C under a load of 2.16 kg, an Mz below 1,000,000 g/mol as determined by size exclusion chromatography, a ratio of complex viscosity at a frequency of 0.01 rad/sec to the complex viscosity at a frequency of 100 rad/sec of at most 8.0, said ratio being measured at 190°C, a tan delta at 0.1 rad at 190°C above 2.5; and a grafting agent content of at least 0.3 wt.% based on total weight of the modified polypropylene composition.

IPC Classes  ?

• C08F 8/46 - Reaction with unsaturated dicarboxylic acids or anhydrides thereof, e.g. maleinisation
• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08J 3/20 - Compounding polymers with additives, e.g. colouring

Abstract

The present disclosure relates to a process to produce a reinforced elastomeric material and to the reinforced elastomeric material. The process comprises the steps of providing components comprising a grafted elastomer, one or more dianhydrides, and one or more diamines; wherein the grafted elastomer is provided at a content of at least 60 wt.% based on the total weight of the components; performing in situ synthesis of a polyimide phase in the grafted elastomer by reactive extrusion of the components in a twin-screw extruder comprising main hopper wherein the screw profile comprises two or more reverse conveying elements forming two or more hot zones to form an elastomer-polyimide blend; and recovering said elastomer-polyimide blend being a reinforced elastomeric material.

IPC Classes  ?

• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers modified by chemical after-treatment
• C08L 51/00 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers
• C08L 51/06 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to homopolymers or copolymers of aliphatic hydrocarbons containing only one carbon-to-carbon double bond

Abstract

The invention relates to a microfluidic device (1) for forming a cell assembly comprising at least one first cell (C1) and one second cell (C2) and for individually treating a selected cell of said cell assembly, comprising: - a microfluidic channel (10); - at least one main inlet (11) for a fluid containing first cells, respectively second cells, arranged in a first portion (101) of the microfluidic channel; - an outlet (12) arranged in a second portion (102) of the microfluidic channel for controlling a fluid flow rate in the microfluidic channel; - at least one first auxiliary inlet (131) for a first auxiliary fluid arranged in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - at least one cell trap (14) arranged in the microfluidic channel between the first portion and the second portion, wherein each cell trap (14) comprises at least one first trapping portion (141) and one second trapping portion (142), each first and second trapping portion being sized to receive a respective first or second cell, said first and second trapping portions being adjacent to each other in a direction perpendicular to a bottom (100) of the microfluidic channel to form the cell assembly with the trapped first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel, - at least one first valve for controlling a flow rate of the first auxiliary fluid so as to cause the fluid containing the first cells, respectively the second cells, to flow at a determined height in the microfluidic channel in order to bring the first cell, respectively the second cell, to the first trapping portion, respectively to the second trapping portion.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to an antigen-binding mutant antibody fragment comprising a mutated heavy chain variable domain, wherein the amino acid residue at position 128 according to the IMGT nomenclature of the heavy chain variable domain is substituted by a cysteine, provided that this fragment is not a Fab fragment in which the mutated heavy chain fragment corresponds to the amino acid sequence SEQ ID NO: 1 and the light chain fragment corresponds to the amino acid sequence SEQ ID NO: 2. The present invention also relates to nucleic acid molecules, vectors and host cells that can be used for the production of the mutant antibody fragment, final and intermediate conjugates comprising same and methods for the production of same, as well as various uses thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 49/00 - Preparations for testing in vivo
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof

Abstract

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinsons disease or Alzheimers disease.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Abstract

Subject of the invention is a method of drying gas and regenerating an adsorbent, comprising the steps: a) proving a gaseous mixture comprising water and at least one further component, wherein the gaseous mixture comprises ≥ 5 vol% H2O, b) contacting the gaseous mixture with an adsorbent, which is an aluminosilicate zeolite which comprises caesium, potassium, sodium, silicon, aluminium and oxygen, such that the aluminosilicate zeolite adsorbs water from the gaseous mixture, and c) regenerating the aluminosilicate zeolite such that the aluminosilicate zeolite desorbs water.

IPC Classes  ?

• B01J 20/18 - Synthetic zeolitic molecular sieves

Abstract

abcxy5656, wherein a is in the range of 3.30 to 5.60, b is in the range of 2.20 to 3.40, c is in the range of 3.30 to 5.00, x is in the range of 14.00 to 20.00, y is in the range of 8.00 to 14.00, and x/y is ≥ 1.35.

IPC Classes  ?

• C01B 39/46 - Other types characterised by their X-ray diffraction pattern and their defined composition

Abstract

2222O and at least one additional component.

IPC Classes  ?

• B01J 20/18 - Synthetic zeolitic molecular sieves
• B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography

Abstract

22 in the presence of a quaternary ammonium halide so as to form cyclic carbonate groups. This method may be included in a plastic recycling method, or may be followed by post-treatment steps.

IPC Classes  ?

• C08F 8/48 - IsomerisationCyclisation

Goods & Services

Software; Software for the calculation and analysis of climate, geographical, mapping, geological data for soil cultivation; Data analysis software relating to soils. Computer software design; Installation of computer software; Maintenance of computer software; Updating of computer software; Rental of computer software; Computer programming; Scientific research; Technical research; Platform as a service featuring a software application for (climate, geographical, mapping, geological) data analysis for soil cultivation; Platform as a service featuring a data simulation software application for use in agriculture; Software as a service (SaaS).

Abstract

The present invention relates to a MEMS switch (101) comprising a substrate (102) on which the following are formed: an input line (103), an output line (104), at least one contact area, a conductive membrane (105) and an activation electrode (206) located under the membrane (105), a dielectric layer (108) and a spacer layer (E) being formed between the membrane (105) and the upper surface of the substrate (102), a metal shield (107) being formed at the interface between the dielectric layer (108) and the spacer layer (E) and covering all or part of the interface between the two layers.

IPC Classes  ?

• H01H 59/00 - Electrostatic relaysElectro-adhesion relays
• H01H 1/00 - Contacts

Abstract

The present invention relates to a method for anodizing at least one portion of a part comprising aluminium or an aluminium alloy, said method comprising the following successive steps: a) immersing said portion in an aqueous bath comprising etidronic acid and polymeric particles comprising at least one fluoropolymer, b) applying to the portion immersed in the bath an electrical current and/or an electrical voltage, so as to obtain on said portion an anode layer incorporating said polymeric particles comprising at least one fluoropolymer, and/or residues of said particulate polymeric particles over its entire thickness. The invention also relates to a surface treatment method comprising said anodizing method, and also to the parts that can be obtained via this surface treatment method. The anode layer thus obtained imparts in particular improved tribological properties to the parts comprising aluminium or an aluminium alloy.

IPC Classes  ?

• C25D 11/10 - Anodisation of aluminium or alloys based thereon characterised by the electrolytes used containing organic acids
• C25D 11/12 - Anodising more than once, e.g. in different baths
• C25D 15/00 - Electrolytic or electrophoretic production of coatings containing embedded materials, e.g. particles, whiskers, wires
• C25D 11/02 - Anodisation
• C25D 11/24 - Chemical after-treatment

Abstract

A method for producing a measuring device (10) with a microflow channel (22) is provided. The device (10) includes an electrical sensing module (30) including at least two electrodes (32, 34) for characterizing objects in fluid flow. The method involves preparation of an SOI substrate (100) including top and bottom semiconductor layers (90, 50) and an intermediate oxide layer (70). The top layer is patterned to form a cavity defining the flow channel, the electrodes and a gap (92) adjacent to the respective electrodes along the flow channel. Then an insulating material (80, 82) is applied to each gap to form an insulating filling (81) for electrically insulating the electrical sensing module from the remaining top layer. The corresponding measuring device (10) is also provided.

IPC Classes  ?

• G01N 15/10 - Investigating individual particles
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects

Abstract

A binder composition in dry weight percentage comprising a) between 1% and 30% of Portland cement, lime or a mixture thereof, b) between 1% and 40% of ground granulated blast furnace slag, c) between 20% and 50% of at least one pozzolanic material, d) between 20% and 65% of at least one filler, e) between 0.5% and 10%, relative to the total weight of components a, b, c, and d, of at least one activator, f) between 0.05% and 1.5%, relative to the total weight of components a, b, c and d, of at least one water reducer polymer, the filler being a mixture between 10% and 90% in weight of particles having a d50≥0.05 μm and <8 μm, and between 10% and 90% in weight of particles having a d50≥8 μm and <200 μm, the filler mixture weight percentages in respect to total weight of the filler.

IPC Classes  ?

• C04B 28/12 - Hydraulic lime
• C04B 14/28 - Carbonates of calcium
• C04B 22/14 - Acids or salts thereof containing sulfur in the anion, e.g. sulfides
• C04B 28/08 - Slag cements
• C04B 103/10 - Accelerators
• C04B 103/30 - Water reducers, plasticisers, air-entrainers

Abstract

The invention relates to an aeronautical thruster comprising a blade, the blade comprising a profiled part (85) having an aerodynamic profile extending radially from the central component, the profiled part (85) having a leading edge (86), a trailing edge (87), a lower surface and an upper surface (89), wherein the lower surface (88) or the upper surface (89) comprise a textured surface portion (90) having a series of projections and/or recesses, the textured surface portion (90) being defined such that any given point of the textured surface portion (90) is located at a radial distance from the main axis of the aeronautical thruster equal to the sum of a minimum radius (Rmin) and between 20% and 95% of a span of the profiled part (85), and is located at an axial distance from the leading edge comprised between 2% and 50% of the local chord length.

IPC Classes  ?

• F01D 5/14 - Form or construction
• B64C 11/18 - Aerodynamic features
• B64C 11/26 - Fabricated blades
• B64D 15/12 - De-icing or preventing icing on exterior surfaces of aircraft by electric heating
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• F01D 25/02 - De-icing means for engines having icing phenomena
• F02C 7/047 - Heating to prevent icing
• B64D 33/02 - Arrangement in aircraft of power plant parts or auxiliaries not otherwise provided for of combustion air intakes

Abstract

The present invention relates to a compound of formula (I) or (I'): A-X (I) A-L-B (I') wherein A and B are each independently a radical of the following formula (II) : The present invention also relates to the use of a compound of formula (I) or (I') as a colouring agent, in particular as a red colouring agent. The present invention also relates to a cosmetic, a pharmaceutical composition or a food product comprising at least one compound of formula (I) or (I').

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups

Abstract

The present invention relates to a method for extracting fatty substances contained in oily sludge, in particular oily sludge from cleaning wastewater works and sanitation networks, comprising the following steps: (a) thermo-mechanically filtering the oily sludge, without any organic solvent, so as to separate the oily sludge into a solid fraction and a liquid fraction, the liquid fraction comprising the fatty substances; (b) collecting the liquid fraction comprising the fatty substances.

IPC Classes  ?

• C02F 11/126 - Treatment of sludgeDevices therefor by de-watering, drying or thickening by mechanical de-watering using drum filters
• C02F 11/13 - Treatment of sludgeDevices therefor by de-watering, drying or thickening by heating
• C02F 101/32 - Hydrocarbons, e.g. oil

Abstract

The present invention relates to a solid polymer electrolyte comprising: a) at least one polymer comprising at least one unit obtained from a reaction of at least one styrenic monomer with at least one polymer P selected from polyethers; and b) at least one electrolyte salt.

IPC Classes  ?

• C08G 65/40 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols and other compounds
• C08G 65/48 - Polymers modified by chemical after-treatment
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type

Abstract

The present invention relates to an assembly comprising a carbon nanotube coated successively with: a primary coating resulting from the polymerisation of an amphiphilic diynic compound bearing an anionic or cationic group; optionally an intermediate coating of a cationic or anionic polymer; and a final coating of a porphyrin derivative which is either an anionic porphyrin or a cationic porphyrin, the coatings being linked to each other by electrostatic interactions. The present invention relates also to a method to prepare such an assembly and to its use as a photocatalyst, especially in a water medium, in particular in oxidation reactions, and for the production of singlet oxygen which is especially useful for disinfection or photodynamic therapy (PDT).

IPC Classes  ?

• B01J 31/06 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
• B01J 21/18 - Carbon
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 35/39 - Photocatalytic properties

Abstract

nkk) defined by a frequency range, for which a value representative of the power spectral density of the signal (x) is greater than a percentage (A) of its average value.

IPC Classes  ?

• G01N 29/024 - Analysing fluids by measuring propagation velocity or propagation time of acoustic waves
• G01N 29/34 - Generating the ultrasonic, sonic or infrasonic waves
• G01N 29/44 - Processing the detected response signal

Abstract

The present invention relates to a donepezil and a derivative or a pharmaceutically acceptable salt and/or solvate thereof new daily low dosage regimens for the prevention and/or the treatment of a compulsive disorder, notably an eating disorder. The present invention also relates to a unit dosage form comprising from 0.25 mg to 2.5 mg of donepezil, a derivative or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in the prevention and/or the treatment of a compulsive disorder, notably an eating disorder.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a donepezil and a derivative or a pharmaceutically acceptable salt and/or solvate thereof new daily low dosage regimens for the prevention and/or the treatment of a compulsive disorder, notably an eating disorder. The present invention also relates to a unit dosage form comprising from 0.5 mg to 2.5 mg of donepezil, a derivative or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in the prevention and/or the treatment of a compulsive disorder, notably an eating disorder.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention relates to a method for detecting and recognizing a partial discharge in electrical equipment (10) in an aeronautical environment, the method comprising a step of detecting (E10), by means of a sensor (91), an electrical signal to be analysed (1), the method being characterized in that it further comprises steps of computing (E2) at least one value of a distance parameter (3) representative of a distance between the electrical signal to be analysed (1) and at least one signature signal (2) representative of a partial discharge, the distance parameter being dependent on a difference between the electrical signal to be analysed and the signature signal, and of comparing (E3) the value of the distance parameter with a detection threshold (4) and detecting a potential partial discharge depending on a result of the comparison.

IPC Classes  ?

• G01R 31/12 - Testing dielectric strength or breakdown voltage
• G01R 31/00 - Arrangements for testing electric propertiesArrangements for locating electric faultsArrangements for electrical testing characterised by what is being tested not provided for elsewhere
• G01R 31/14 - Circuits therefor
• H02H 1/00 - Details of emergency protective circuit arrangements

Abstract

The present invention provides a new method that is specifically designed to start statistically from a single copy of a nucleic acid molecule and requires only a single encapsulation step to provide clonal microcompartment libraries displaying a high concentration of encoded polypeptides. The method of the invention enables one to perform in vitro uHTS via a one-step encapsulation of linear DNA constructs containing a candidate sequence to be tested in a molecular mixture that allows for simultaneous specific gene amplification and protein expression.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to pharmaceutical compositions comprising a benzene sulfonamide thiazole compound, to their use as medicament and to their use in the prevention and/or treatment of cancers.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/426 - 1,3-Thiazoles
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The disclosure relates to a process to produce a polymer composition comprising melt blending from 10 to 90 wt.% of polyethylene resins; from 90 to 10 wt.% of materials selected from materials having a polar functional group, inorganic polar particles, polymers having a polar functional group, HD silica, fumed silica, carbon-containing particles, carbon fibres, glass fibres, natural fibres, and any mixture thereof; from 0.5 to 20 wt.% of a grafted polyethylene, and the compatibilizer is comprising at least 70 wt.% of polyethylene based on the total weight of the compatibilizer, and has a melt index MI2 ranging from 25 to 450.0 g/10 min, an Mw/Mn ranging from 2.0 to 4.5; a complex viscosity at 0.1 rad/sec at 190 °C of at most 25,000 Pa·s; and a grafting agent content ranging from 0.5 to 15.0 wt.% based on the total weight of the compatibilizer.

IPC Classes  ?

• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08L 23/06 - Polyethene
• C08L 77/00 - Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chainCompositions of derivatives of such polymers

Abstract

The present invention relates to a computer-implemented method for determining at least one therapeutic target region on a candidate protein of a target pathogenic organism, said method comprising the following steps: a) identifying (E1), in a set of previously aligned nucleotide and polypeptide sequences characteristic of said candidate protein, invariant residues and/or pairs of lethal synthetic residues referred to as target residues; b) identifying (E2) at least one candidate region consisting of at least one pair of target residues identified in step a), said at least one pair comprising target residues located at a determined distance in space and being exposed at the surface of the candidate protein, preferably in a pocket; c) determining (E3) the advantageous chemical interactions between each residue and/or between each pair of residues within the candidate protein, from the 2D and/or 3D structure of the candidate protein; said advantageous chemical interactions being hydrophobic bonds and/or hydrogen bonds and/or saline bridges and/or negative-repulsion and/or positive-repulsion bonds; d) selecting (E4) the residues linked by said advantageous chemical interactions, said residues being at a distance of at most 10 angstroms; e) selecting (E5) at least one therapeutic target region from among the candidate regions identified in step b), comprising the residues selected in step d).

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction

Abstract

Clostridium acetobutylicumcip-celcip-celClostridium acetobutylicumClostridium acetobutylicumClostridium acetobutylicum, as well as derivatives thereof with further modifications increasing growth on lignocellulosic biomass, and the use of these strains for the production of bulk chemicals by conversion of lignocellulose as source of carbon, such as ethanol, butanol, glycerol, 1,2-propanediol, acetone, isopropanol, isobutene, hydrogen, acetic acid and lactic acid and the like.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present disclosure relates to a wireless energy transfer system and respective use. It is disclosed a thermoplasmonic device for harvesting energy from incident light. It is also disclosed a wireless energy transfer system for transferring energy comprising the thermoplasmonic device and a light source for emitting incident light onto said device.

IPC Classes  ?

• G02B 5/00 - Optical elements other than lenses
• H02S 10/30 - Thermophotovoltaic systems

Abstract

The invention relates to a device (1) for detection of boron blockage in a conduit (C) for the passage of borated water, characterized in that the device comprises a neutron emission source (2), a neutron detector (3), a support (4), a measurement counter (5) supplying a measurement of boron blockage according to a measurement of the number of neutrons that are detected by the detector (3), the support (4) being able to keep the detector (3) oriented towards the source (2), so that the path distance (D) travelled by the neutrons from the source (2) to the detector (3) can be occupied at least in part by the conduit (C).

IPC Classes  ?

• G21C 17/01 - Inspection of the inner surfaces of vessels
• G01N 23/09 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and measuring the absorption the radiation being neutrons
• G21C 17/04 - Detecting burst slugs

Abstract

The present invention relates to a method for inducing proximity between two biological molecules in a sample, to an assay relying on the induction of proximity between two biological molecules in a sample, and to a proximity inducing system comprising two polypeptides and a molecular inducer of proximity.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07D 277/34 - Oxygen atoms

Abstract

The present invention relates to humanized antibodies having specificity to Nectin-4 and uses thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a microelectromechanical systems (MEMS) switch (201'), comprising a substrate (202'), at least one signal input line (203'), at least one signal output line (204'), at least one contact zone formed on a contact zone base (206'a, 206'b) integral with the substrate, and a contact membrane (205') held by at least one anchoring base (206'c) integral with the substrate, wherein, for each contact zone, the contact membrane (205') constitutes a first entity, the contact base (206'a, 206'b) constitutes a second entity and the at least one anchoring base (206'c) constitutes a third entity, and at least two entities from among the first entity, the second entity and the third entity are deformable, each by an independent actuating means, in order to move the contact membrane towards or away from the contact zone.

IPC Classes  ?

• H01H 59/00 - Electrostatic relaysElectro-adhesion relays

Abstract

The method can be applied to a quantum system having a non-linear element coupled to a resonator, the non-linear element having a quantum state changeable between a plurality of quantum states and the resonator having a resonance frequency. The method can include driving the resonator; the resonator resonating at a first frequency in response to said driving the resonator; and simultaneously to said driving the resonator, driving the non-linear element at the first frequency.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco- supplementation (a lubricating effect).

IPC Classes  ?

• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to novel anti Nectin-4 antibodies and antibody-drug conjugates comprising these antibodies, as well as to the use thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an agonist of the colony stimulating factor 1 receptor (CSF1R) for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression in a subject and to pharmaceutical compositions comprising said CSF1R agonist. According to the invention, said subject is in a state of immunosuppression, when in said subject the absolute number of CD14+, CD16+ und HLA-DR+ expressing monocytes is reduced when compared to a healthy control subject. The invention is based on the finding that CSF 1R agonist treatment, such as M-CSF treatment, induces an integrated multistep differentiation cascade that culminated in increased NK cell activation protecting HCT recipients from a viral infection. A mechanism of action by which M-CSF-induced myelopoiesis can rapidly reconstitute antiviral activity under immunosuppressed conditions was identified, which provides a general paradigm to boost innate antiviral immune response.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 31/12 - Antivirals
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Abstract

The invention relates to a method for characterising microorganisms present in a biological sample, the method comprising acquiring a live holographic digital image of the sample, generating a focused image by using a digital model for reconstructing the focused image and characterising the bacteria on the basis of the focused image. According to the invention, prior to the holographic image being acquired, a plurality of calibration objects are provided in the acquisition field of view, which objects have a previously characterised dimension and refractive index and a shape chosen so that the interference patterns of the objects can be calculated using an image forming model for incorporating optical aberrations of the acquisition device. Prior to the focused image being computer generated, the optical aberrations are qualified according to the interference patterns of the objects and the calculated interference patterns and the digital model for reconstructing the focused image incorporates the quantified optical aberrations.

IPC Classes  ?

• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G03H 1/08 - Synthesising holograms
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/10 - Investigating individual particles
• G06T 7/00 - Image analysis
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06T 5/00 - Image enhancement or restoration
• G02B 21/00 - Microscopes

Abstract

The present invention relates to an engineered unicellular Stramenopile microalga comprising a loss of function of the homologous Seipin gene, an in vitro method of producing triacylglycerols (TAG), and uses thereof.

IPC Classes  ?

• C07K 14/405 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from algae
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12R 1/89 - Algae

Abstract

The present invention relates to a compound of the following formula (A) mainly for use as a radiopaque monomer: The invention further relates to radiopaque embolisation microspheres based at least on: 20% to 90% hydrophilic monomer; 5% to 50% compound of formula (A); 1% to 15% non-biodegradable hydrophilic crosslinking monomer; and - 0.1% to 10% transfer agent. The invention also relates to a pharmaceutical composition comprising at least one embolisation microsphere according to the invention, in association with a pharmaceutically acceptable carrier, advantageously for parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition according to the invention in association with a pharmaceutically acceptable carrier for parenteral administration, and to an injection means.

IPC Classes  ?

• A61K 49/04 - X-ray contrast preparations
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
• C08F 220/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 226/10 - N-Vinyl-pyrrolidone
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/50 - Microcapsules

Abstract

The invention relates to a quantitative phase imaging device (1) comprising: - an optical imaging system (3) for imaging an object (14) in an image plane, - a light source (2) for emitting light radiation (I) onto the Fourier plane (C) of the optical imaging system, - an optical spatial filter (4) in the Fourier plane having a zone of least attenuation (41) and a zone of greatest attenuation (42), - a wavefront sensor (5) for measuring, in the image plane, the intensity and the phase of the light radiation that has passed through the optical imaging system and the optical spatial filter, and at least some of which light radiation has interacted with the object, in order to quantify the phase induced by the object, the light source, the optical imaging system and the optical spatial filter being such that, in the absence of the object, the light radiation (I) is focused on the zone of greatest attenuation.

IPC Classes  ?

• G02B 21/14 - Condensers affording illumination for phase-contrast observation

Abstract

The present invention relates to an anti-mGLUR2 biparatopic nanobody comprising : (i) one single domain antibody having a CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2and a CDR3 having a sequence set forth as SEQ ID NO:3; or a CDR1 having a sequence set forth as SEQ ID NO:4, a CDR2 having a sequence set forth as SEQ ID NO:5 and a CDR3 having a sequence set forth as SEQ ID NO:6; or a CDR1 having a sequence set forth as SEQ ID NO:7, a CDR2 having a sequence set forth as SEQ ID NO:8 and a CDR3 having a sequence set forth as SEQ ID NO:9; preferably a CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2 and a CDR3 having a sequence set forth as SEQ ID NO:3; and (ii) another single domain antibody having a CDR1 having a sequence set forth as SEQ ID NO:10, a CDR2 having a sequence set forth as SEQ ID NO:11 and a CDR3 having a sequence set forth as SEQ ID NO:12; or a CDR1 having a sequence set forth as SEQ ID NO:13, a CDR2 having a sequence set forth as SEQ ID NO:14 and a CDR3 having a sequence set forth as SEQ ID NO:15; or a CDR1 having a sequence set forth as SEQ ID NO:16, a CDR2 having a sequence set forth as SEQ ID NO:17 and a CDR3 having a sequence set forth as SEQ ID NO:18.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to a polypeptide comprising at least one single domain antibody directed against mGluR2 for use as a biomolecule transporter crossing the blood- brain barrier (BBB), with the proviso that the polypeptide does not comprise another binding domain directed against a receptor on the vascular endothelium of the blood- brain barrier or a Fc portion of an immunoglobulin binding domain. In particular, the said polypeptide is used for transporting detectable label or therapeutic agent.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to optimised microbubbles, in particular lipid microbubbles, which can be used in the prevention and treatment of diseases or else labelling. The invention relates in particular to a lipid microbubble comprising at least one cationic compound chosen from lipophosphoramidates, histidyl polyethyleneimines, and any mixture thereof. The microbubble preferably also comprises at least one agent chosen from a therapeutic agent, a targeting agent, a labelling agent, and any combination thereof. The invention also relates to a method for producing this microbubble. The present invention also relates to a composition, in particular a pharmaceutical composition, and a kit, comprising at least one of these microbubbles. The present invention also relates to the use of these microbubbles, composition, kit, as a medicament or as a labelling agent.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61P 35/00 - Antineoplastic agents
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Abstract

The invention relates to a method for anonymized communication between a client device (C) and a server (S) by way of a computing network (1), the computing network being organized into a plurality of groups (gC, g1, g2, g3), each group of said plurality of groups being associated with at least one attribute, each group comprising a plurality of computing devices (LBc, C, LB1, R1, LB2, R2, LB3, R3), each computing device of a group possessing the attribute of said group, for each group, one of the computing devices (LB C, LB1, LB2, LB3) being designated as the supervisor device of said group, the client belonging to one of the groups.

IPC Classes  ?

• H04L 47/10 - Flow controlCongestion control
• H04L 47/35 - Flow controlCongestion control by embedding flow control information in regular packets, e.g. piggybacking
• H04L 9/40 - Network security protocols
• H04L 45/00 - Routing or path finding of packets in data switching networks
• H04L 45/64 - Routing or path finding of packets in data switching networks using an overlay routing layer

Abstract

The present invention relates to a method for manufacturing acrylated epoxidised plant oil particles comprising the following steps: a) mixing acrylated epoxidised plant oil with at least one solvent and in the presence of at least one photoinitiator; b) optionally mixing the solution after step a) with a solution S1; c) mixing the solution obtained after step a) or after optional step b) with an aqueous solution comprising at least one surfactant in order to obtain droplets; d) exposing said droplets to a UV light; e) retrieving the acrylated epoxidised plant oil particles obtained after step d).

IPC Classes  ?

• C10M 145/22 - Polyesters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• C08F 2/24 - Emulsion polymerisation with the aid of emulsifying agents
• C08F 2/48 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
• C08L 91/02 - Vulcanised oils, e.g. factice

Abstract

The invention relates to ESM-1 (Endothelial cell Specific Molecule) or a pharmaceutical composition containing it for use in a method for treating or preventing acute respiratory distress syndrome (ARDS) in a patient.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/12 - Antivirals
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention relates to a method for bonding a layer of elastomeric material (CE) to an aluminium substrate (SM), characterised in that it comprises carrying out the following steps: a) treating the surface (S) of the aluminium substrate (SM) so as to roughen it; b) treating the surface (S) by means of an argon plasma; c) exposing the surface (S) to a plasma, in the presence of a gaseous chemical precursor, the precursor being chosen from the epoxides, acrylics, alkenes, alkynes and imides, until a deposit of chemical species with a thickness of between 5 and 110 nanometres is obtained; d) placing the layer of elastomeric material (CE) in contact with the surface (S) of the aluminium substrate (SM); and e) vulcanising the layer of elastomeric material; said step c) being carried out at low pressure, i.e. under a pressure of between 10-2 and 10-5 mbar.

IPC Classes  ?

• B29C 65/64 - Joining a non-plastics element to a plastics element, e.g. by force
• B05D 1/00 - Processes for applying liquids or other fluent materials
• B05D 3/14 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by electrical means
• B29C 65/00 - Joining of preformed partsApparatus therefor

Abstract

The invention relates to a device for examining the anterior part of the eye by retro-illumination of said anterior part. This device has means for illuminating the eye, comprising a light source (1), and means for imaging the anterior part of the eye. The invention consists in the device further comprising means of modulating at least one region of the light beam emitted from the light source (1).

IPC Classes  ?

• A61B 3/15 - Arrangements specially adapted for eye photography with means for aligning, spacing or blocking spurious reflection

Abstract

The present invention pertains to cell culture protocols and particularly provides a method for obtaining Invariant Natural Killer T (iNKT) cells. The method according to the present invention particularly comprises culturing peripheral blood mononuclear cells (PBMC) in a culture medium comprising alpha-Galactosylceramide (alpha-GalCer) and Interleukin 15 (IL-15). The present invention allows for the specific expansion of CD4- iNKT which have a particular interest in the prevention of graft versus host disease in the context of hematopoietic stem cell transplantation.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a method for determining the properties of resistance to beta-lactam antibiotics of a strain of enterobacteria present in a biological sample, which method comprises the steps of: a) lysis of the bacteria and hydrolysis of the bacterial proteins in order to obtain a mixture of peptides, b) analysis of this mixture of peptides by targeted mass spectrometry coupled with reverse phase liquid chromatography, detection of at least one specific peptide of an enzyme exhibiting extended spectrum beta-lactamase (ESBL) activity being indicative of the resistance to beta-lactams of the strain of enterobacteria present in the biological sample, the method being characterised in that the analysis step (b) is carried out in the presence of an ion pairing reagent (IPR) added into the chromatography column or into the mixture of peptides.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/10 - Enterobacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for preparing at least one glycolipid according to the following formula (I): [Glc]n-xOy-R (I) [Glc]n representing a linear or branched osidic motif comprising n glucosyl units, where n is between 1 and 7, with the condition that when the osidic motif comprises a plurality of glucosyl units, the latter are linked to one another by α-osidic bonds; R representing a fatty acid radical comprising between 4 and 24 carbon atoms, the carbon chain of which is linear or branched, saturated or unsaturated; -xOy- symbolising the attachment of the fatty acid radical to the osidic motif via an ether bond linking a carbon atom Cx of a glucosyl residue of the osidic motif, previously bearing a hydroxyl group, to a carbon atom Cy of the fatty acid radical, previously bearing a hydroxyl group, where Cx is the position of the atom of the glucosyl residue to which the bond is made, Cx representing the carbon atom C1 of the glucosyl residue, Cy being a carbon atom positioned along the carbon chain of the fatty acid radical or at the omega end thereof; the method comprising a step of glucosylating a hydroxylated fatty acid of formula (II): R-yOH (II) -yOH representing a hydroxyl group attached to a carbon atom Cy as defined above; the step comprising bringing the hydroxylated fatty acid of formula (II) into contact with at least one α-transglucosylase of the GH70 family in the presence of saccharose or a saccharose analogue.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• C11D 1/06 - Ether- or thioether carboxylic acids
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 25/04 - Dispersions or gels
• A61K 8/73 - Polysaccharides
• A61K 8/06 - Emulsions
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The invention relates to a non-destructive inspection method based on 3D modelling of a part (200), comprising: - using an x-ray device (100) to acquire images of the part at various projection angles (I(n)); - computing projections based on the images acquired at the various projection angles; - in each of multiple iterations: - generating simulated projections corresponding to the computed projections, based on a reference model of an external surface of the part and on a vector µ of transformation parameters of the reference model; - modifying the vector µ with a view to reducing a discrepancy between the simulated projections and the computed projections; - determining a corrected model of the external surface through transformation of the reference model by way of the vector µ resulting from the iterations; - determining an effective model of the part by way of the corrected model.

IPC Classes  ?

• G01N 23/046 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using tomography, e.g. computed tomography [CT]
• G01B 15/04 - Measuring arrangements characterised by the use of electromagnetic waves or particle radiation, e.g. by the use of microwaves, X-rays, gamma rays or electrons for measuring contours or curvatures
• G06T 7/60 - Analysis of geometric attributes

Abstract

The invention relates to a chimeric protein comprising three covalently linked domains: - a RNA-guided DNA endonuclease; - a flexible peptide linker; and - a switchable receptor binding domain, the endonuclease activity depending on the uncaging of a caged specific ligand of said switchable receptor binding domain.

IPC Classes  ?

• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The invention relates to a polypeptide which is less than or equal to 60 amino acids in size and which comprises the sequence chosen from the C-terminal sequence of the GPRC5A (G protein-coupled receptor class C group 5 member A) protein ranging from residue 321 to residue 357 of the human GPRCA5 protein (SEQ ID No.: 1), orthologues of same, and fragments thereof or derivatives thereof; and to the use thereof for promoting and/or accelerating the healing of a skin lesion in a subject, preferably for promoting and/or accelerating re-epithelialization.

IPC Classes  ?

• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP/PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).

IPC Classes  ?

• C07K 14/52 - CytokinesLymphokinesInterferons
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/00 - Medicinal preparations containing peptides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a method for estimating the state of charge of a battery, the method comprising the following steps: • - determining the stored state of charge; • - determining the open-circuit instantaneous voltage of the battery according to a predetermined map and the stored state of charge; • - measuring the instantaneous voltage across the terminals of the battery; • - determining the available state of charge according to the stored state of charge, the instantaneous voltage, the open-circuit instantaneous voltage and the minimum acceptable voltage; • - the minimum acceptable voltage being predetermined by design.

IPC Classes  ?

• G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
• G01R 31/3835 - Arrangements for monitoring battery or accumulator variables, e.g. SoC involving only voltage measurements
• G01R 31/3842 - Arrangements for monitoring battery or accumulator variables, e.g. SoC combining voltage and current measurements
• G01R 31/385 - Arrangements for measuring battery or accumulator variables
• G01R 31/387 - Determining ampere-hour charge capacity or SoC
• G01R 31/388 - Determining ampere-hour charge capacity or SoC involving voltage measurements

Abstract

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: - a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; - a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b);15 - a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The invention relates to an aqueous lubricant composition comprising at least: - water; - at least one polyalkylene glycol; - at least one antifreeze compound selected from glycols, preferably alkylene glycols; glycerol; diglycerol; triglycerol, and mixtures thereof; - at least one ascorbic acid ester; and - at least one pH-regulating additive, making it possible to maintain the pH of said lubricant composition between (8) and (15). It also relates to the use of such an aqueous lubricant composition, for lubricating and/or cooling the moving parts in a mechanical system or as a hydraulic fluid. The invention also relates to the use of at least one ascorbic acid ester as an additive for improving the tribological properties of an aqueous lubricant composition.

IPC Classes  ?

• C10M 173/02 - Lubricating compositions containing more than 10% water not containing mineral or fatty oils
• C10M 129/76 - Esters containing free hydroxy or carboxyl groups
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 30/06 - OilinessFilm-strengthAnti-wearResistance to extreme pressure
• C10N 30/12 - Inhibition of corrosion, e.g. anti-rust agents, anti-corrosives
• C10N 40/08 - Hydraulic fluids, e.g. brake-fluids
• C10N 40/25 - Internal-combustion engines
• C10N 40/04 - Oil-bathGear-boxesAutomatic transmissionsTraction drives

Abstract

The invention relates to a stator part (20) comprising a platform (22), a first blade (24), a second blade (26), and a fin (28) having a leading edge (30) and a trailing edge (32), the fin extending opposite an upper surface (124) of the first blade and a lower surface (126) of the second blade, the leading edge comprising a leading point (34) located on the platform, a tangent to the leading edge at the leading point extending between the first blade and a radial leading plane (Pa) and the leading point, and the trailing edge comprising a trailing point (36) located on the platform, a tangent to the trailing edge at the trailing point extending between the second blade and a radial trailing plane (Pf) and the trailing point.

IPC Classes  ?

• F01D 5/14 - Form or construction
• F01D 9/04 - NozzlesNozzle boxesStator bladesGuide conduits forming ring or sector

Abstract

The invention relates to a stator part (20) of a turbine engine, comprising a platform (22), a blade (24, 26) extending radially relative to a central axis (A), and a fin (28) extending radially from a fin root (44) to a fin tip (46), the fin comprising a lower side (48) and an upper side (50), each point (100) of the lower side or of the upper side defining a radial axis (Ar) passing through the point, each plane (Pr) that includes the radial axis defining a section (S) of the lower side or of the upper side, an angle defined in the plane between the root profile and a tangent to the section at an intersection (104) of the section and of the root profile being less than or equal to 45 degrees, the section being located between the root profile and the tangent.

IPC Classes  ?

• F01D 5/14 - Form or construction
• F01D 9/04 - NozzlesNozzle boxesStator bladesGuide conduits forming ring or sector

Abstract

Despite aggressive radio/chemotherapy regimens, pediatric high-grade gliomas (pHGG) are deadly brain tumors that remain incurable and are the leading cause of cancer-related death in children. By analysing the impact of H3.3 mutations on DNA repair and genome integrity maintenance capacities of glioma cells, the present inventors identified the PNKP enzyme as being a major protein partner interacting with mutated H3 oncohistone specifically, and involved in DNA aberrant repair. They showed that inhibition of this enzyme prevents the proliferation of glioma tumor cells bearing specific H3 oncohistone mutations. They therefore propose to target this enzyme in order to efficiently treat patients suffering from gliomas, in particular pediatric gliomas bearing these specific H3 oncohistone mutations, or to sensitize them to current radio/chemotherapeutic regimens, for which there is very limited response.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

A bioink comprises a cell solution comprising living cells and a cell culture medium, and a self-assembling peptide solution comprising a self-assembling peptide. The bioink is formed by mixing and extruding the cell solution and the self-assembling peptide solution together, and the bioink can be continuously extruded from the mixer after mixing. Useful methods of making bioinks and are also disclosed.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 31/04 - Macromolecular materials

Abstract

A jammed gel bioink comprises a self-assembling peptide solution comprising a self-assembling peptide, and a cell solution comprising living cells and a cell culture medium. The self-assembling peptide solution is extruded to form an object, and then the cell solution is injected into the object. Useful methods of making the jammed gel bioink are also disclosed.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 31/04 - Macromolecular materials

Abstract

According to one aspect, the invention relates to a phased array antenna comprising: - a plurality of elementary antennas, - an amplifier circuit (AMPC) for each elementary antenna (ANTE), the amplifier circuit (AMPC) comprising: a power amplifier (PA) configured to amplify at least two useful signals of different frequencies to be transmitted by the elementary antenna, and a third-order intermodulation product control circuit (ICTRL) configured to control a third-order intermodulation product phase generated by the amplifier circuit so as to control an orientation of third-order intermodulation product radiation transmitted by the phased array antenna.

IPC Classes  ?

• H04B 1/04 - Circuits
• H03F 1/32 - Modifications of amplifiers to reduce non-linear distortion

Abstract

The present disclosure relates to compositions comprising collagen microparticles comprising more than 90% by weight of collagen, biomimetic hydroxyapatite or biomimetic hydroxyapatite precursors and a physiologically compatible aqueous solvent for use in dentine repair.

IPC Classes  ?

• A61K 6/17 - Particle size
• A61K 6/60 - Preparations for dentistry comprising organic or organo-metallic additives
• A61K 6/74 - Fillers comprising phosphorus-containing compounds
• A61K 6/75 - Apatite
• A61K 6/838 - Phosphorus compounds, e.g. apatite
• A61K 6/891 - Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds